EGFR and non-small cell lung carcinoma: Thus, the efficacy of ICI plus chemotherapy in NSCLC patients with EGFR-TKI resistance remains controversy, suggesting that this population may has large heterogeneity, and the searching for efficacy biomarkers might be an effective way to screen and enrich population to benefit and improve the efficiency of treatment.